Company intelligence / Profile preview
Kalaris Therapeutics, Inc.
Palo Alto, California, United Stateskalaristx.com ↗
- Ownership
- Private
- Employees
- ~14
- Development stage
- Phase 1
01
Overview
Currently developing TH103, a novel anti-VEGF agent in Phase 1 clinical trial for nAMD. Initial data from Part 1 of the trial is expected in the second half of 2025. TH103 has demonstrated potent anti-VEGF activity and sustained ocular residence time in preclinical studies.
- Therapeutic areas
- Ophthalmology
- Modalities
- Recombinant fusion protein
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Beyond the preview
Go deeper on Kalaris Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kalaris Therapeutics, Inc..